Trial · NCT03988335
A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
NCT03988335, Phase 2, Completed, Aristea Therapeutics, Inc.; results first posted 2022-03-03
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP). Trials, record NCT03988335. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03988335
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
- NCT number
- NCT03988335
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 35 participants, actual
- Lead sponsor
- Aristea Therapeutics, Inc.
- Conditions
- Palmoplantar Pustulosis
- Interventions
- RIST4721, Placebo
- First posted
- 2019-06-17
- Last updated
- 2022-04-05
- Results first posted
- 2022-03-03
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Log Transformed Ratio of Postbaseline Fresh Pustule Count at Day 28 to Baseline | Baseline to Day 28 | Relative change from baseline in fresh pustule count at Day 28 |
| Primary | Log Transformed Ratio of Postbaseline Total Pustule Count at Day 28 to Baseline | Baseline to Day 28 | Relative change from baseline in total pustule count at Day 28 |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Log Transformed Ratio of Postbaseline Fresh Pustule Count at Day 28 to Baseline | Baseline to Day 28 | Log transformed ratio | MEAN | |
| PRIMARY | Log Transformed Ratio of Postbaseline Total Pustule Count at Day 28 to Baseline | Baseline to Day 28 | Log transformed ratio | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Log Transformed Ratio of Postbaseline Fresh Pustule Count at Day 28 to Baseline | RIST4721 300 mg | 0.86 | Standard Deviation 0.692 | Log transformed ratio | |
| Log Transformed Ratio of Postbaseline Fresh Pustule Count at Day 28 to Baseline | Placebo | 0.53 | Standard Deviation 0.561 | Log transformed ratio | |
| Log Transformed Ratio of Postbaseline Total Pustule Count at Day 28 to Baseline | RIST4721 300 mg | 0.99 | Standard Deviation 0.667 | Log transformed ratio | |
| Log Transformed Ratio of Postbaseline Total Pustule Count at Day 28 to Baseline | Placebo | 0.96 | Standard Deviation 0.672 | Log transformed ratio |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | RIST4721 | 16 | |
| Overall Study | STARTED | Placebo | 19 | |
| Overall Study | COMPLETED | RIST4721 | 14 | |
| Overall Study | COMPLETED | Placebo | 18 | |
| Overall Study | NOT COMPLETED | RIST4721 | 2 | |
| Overall Study | NOT COMPLETED | Placebo | 1 |
Source ClinicalTrials.gov
Adverse events64
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Fatigue | General disorders | RIST4721 300 mg | 1 | 15 | 1 |
| other | Fatigue | General disorders | Placebo | 0 | 19 | 0 |
| other | Anxiety | Psychiatric disorders | RIST4721 300 mg | 1 | 15 | 1 |
| other | Anxiety | Psychiatric disorders | Placebo | 0 | 19 | 0 |
| other | Vaginal haemorrhage | Reproductive system and breast disorders | RIST4721 300 mg | 0 | 15 | 0 |
| other | Vaginal haemorrhage | Reproductive system and breast disorders | Placebo | 1 | 19 | 1 |
| other | Procedural pain | Injury, poisoning and procedural complications | RIST4721 300 mg | 2 | 15 | 2 |
| other | Procedural pain | Injury, poisoning and procedural complications | Placebo | 1 | 19 | 1 |
| other | Ligament sprain | Injury, poisoning and procedural complications | RIST4721 300 mg | 0 | 15 | 0 |
| other | Ligament sprain | Injury, poisoning and procedural complications | Placebo | 1 | 19 | 1 |
1 to 10 of 64Source ClinicalTrials.gov
See all 64 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | RIST4721 300 mg | 0 | 15 |
| Total, all-cause mortality | Placebo | 0 | 19 |
| Total, other adverse events | RIST4721 300 mg | 13 | 15 |
| Total, other adverse events | Placebo | 7 | 19 |
| Total, serious adverse events | RIST4721 300 mg | 0 | 15 |
| Total, serious adverse events | Placebo | 0 | 19 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 34716902 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| RIST4721 300 mg vs Placebo: deaths from any cause | Trial comparisons |
| RIST4721 300 mg vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03988335
GET https://conductscience.org/api/trials/v1/NCT03988335/events?page=2